2014年非酒精性脂肪性肝病诊治进展*

doi:10.3969/j.issn.1672-5069.2015.01.003

Abstract

Xun Yunhao, Shi Junping. Progress in the diagnosis and management of nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 6-9.

[1] Obesity:a growing threat to health in China. Lancet,2014,384:716.
[2] Yeh MM,Brunt EM. Pathological features of fatty liver disease. Gastroenterology,2014,147:754-764.
[3] Musso G,Gambino R,Cassader M,et al. Meta-analysis:natural history of non-alcoholic fatty liver disease（NAFLD） and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med,2011,43:617-649.
[4] Joka D,Wahl K,Moeller S,et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology,2012,55:455-464.
[5] 钱建成,陆璐,娄国强,等. 血清细胞角蛋白18诊断非酒精性脂肪性肝病的价值探讨. 实用肝脏病杂志,2012,15（4）:291-294.
[6] Chan WK,Sthaneshwar P,Nik Mustapha NR,et al. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis a comparison with routine biochemical markers. PLoS One,2014,9:e105903.
[7] Chen J,Zhu Y,Zheng Q,et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis:A meta-analysis. Hepatol Res,2014,44:854-862.
[8] Otgonsuren M,Estep MJ,Hossain N,et al. A single non-invasive model to diagnose non-alcoholic fatty liver disease （NAFLD） and non-alcoholic steatohepatitis（NASH）. J Gastroenterol Hepatol,2014,Jul 6. doi:10.1111/jgh.12665.[Epub ahead of print].
[9] Bastati N,Feier D,Wibmer A,et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease:a proof-of-concept study. Radiology,2014,271:739-747.
[10] Issa L,Goh GB,Lopez R,et al. The development of a non-invasive model to predict the presence of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology,2014,57 （Suppl 1）:883A.
[11] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology. Gastroenterology,2012,142:1592-1609.
[12] Musso G,Cassader M,Rosina F,et al. Impact of current treatments on liver disease,glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease（NAFLD）:a systematic review and meta-analysis of randomised trials. Diabetologia,2012,55:885-904.

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[4]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[5]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[6]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[7]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[8]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[9]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[10]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[11]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[14]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[15]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.

Progress in the diagnosis and management of nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments